BR112014006871A2 - fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpo - Google Patents

fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpo

Info

Publication number
BR112014006871A2
BR112014006871A2 BR112014006871A BR112014006871A BR112014006871A2 BR 112014006871 A2 BR112014006871 A2 BR 112014006871A2 BR 112014006871 A BR112014006871 A BR 112014006871A BR 112014006871 A BR112014006871 A BR 112014006871A BR 112014006871 A2 BR112014006871 A2 BR 112014006871A2
Authority
BR
Brazil
Prior art keywords
producing
antibody
alleviating
abnormalities
vaccine
Prior art date
Application number
BR112014006871A
Other languages
English (en)
Portuguese (pt)
Inventor
Pfeifer Andrea
Muhs Andreas
Vasilyevich Belichenko Pavel
Madani Rime
Charles Mobley William
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of BR112014006871A2 publication Critical patent/BR112014006871A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112014006871A 2011-09-23 2012-09-21 fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpo BR112014006871A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23
PCT/US2012/056728 WO2013044147A1 (en) 2011-09-23 2012-09-21 Vaccine therapy

Publications (1)

Publication Number Publication Date
BR112014006871A2 true BR112014006871A2 (pt) 2017-04-04

Family

ID=47018510

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006871A BR112014006871A2 (pt) 2011-09-23 2012-09-21 fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpo

Country Status (23)

Country Link
US (2) US20140314837A1 (cg-RX-API-DMAC7.html)
EP (1) EP2758071B1 (cg-RX-API-DMAC7.html)
JP (1) JP6110861B2 (cg-RX-API-DMAC7.html)
KR (3) KR20160099732A (cg-RX-API-DMAC7.html)
CN (2) CN104039346A (cg-RX-API-DMAC7.html)
AU (1) AU2012312126B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014006871A2 (cg-RX-API-DMAC7.html)
CA (1) CA2811188C (cg-RX-API-DMAC7.html)
DK (1) DK2758071T3 (cg-RX-API-DMAC7.html)
EA (1) EA032494B1 (cg-RX-API-DMAC7.html)
ES (1) ES2712951T3 (cg-RX-API-DMAC7.html)
HU (1) HUE041277T2 (cg-RX-API-DMAC7.html)
IL (1) IL231564A0 (cg-RX-API-DMAC7.html)
MX (1) MX350928B (cg-RX-API-DMAC7.html)
MY (1) MY169574A (cg-RX-API-DMAC7.html)
PH (1) PH12014500657A1 (cg-RX-API-DMAC7.html)
PL (1) PL2758071T3 (cg-RX-API-DMAC7.html)
PT (1) PT2758071T (cg-RX-API-DMAC7.html)
SG (1) SG11201400795UA (cg-RX-API-DMAC7.html)
SI (1) SI2758071T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901846T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013044147A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402071B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗
WO2024156912A1 (en) 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009831A1 (en) 1997-08-28 1999-03-04 Ajay North America Methods and compositions for protecting plants and crops
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
SI2336147T1 (sl) * 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
AU2005290250A1 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
CA2690434C (en) * 2007-06-12 2018-05-22 Ac Immune S.A. Monoclonal anti beta amyloid antibody
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
EP2632434B1 (en) * 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties

Also Published As

Publication number Publication date
EP2758071A1 (en) 2014-07-30
EA201400376A1 (ru) 2014-09-30
US20140314837A1 (en) 2014-10-23
EA032494B1 (ru) 2019-06-28
JP2014531455A (ja) 2014-11-27
WO2013044147A1 (en) 2013-03-28
HUE041277T2 (hu) 2019-05-28
AU2012312126A1 (en) 2014-03-27
PT2758071T (pt) 2019-01-11
CN109847058A (zh) 2019-06-07
JP6110861B2 (ja) 2017-04-05
ES2712951T3 (es) 2019-05-16
PH12014500657A1 (en) 2014-05-05
IL231564A0 (en) 2014-04-30
AU2012312126B2 (en) 2016-11-10
PL2758071T3 (pl) 2019-08-30
CA2811188A1 (en) 2013-03-23
MY169574A (en) 2019-04-22
DK2758071T3 (en) 2019-02-18
MX2014003325A (es) 2014-05-21
KR20160005380A (ko) 2016-01-15
NZ622653A (en) 2015-12-24
CA2811188C (en) 2020-04-28
SG11201400795UA (en) 2014-10-30
ZA201402071B (en) 2017-08-30
TR201901846T4 (tr) 2019-03-21
SI2758071T1 (sl) 2019-01-31
US20240270829A1 (en) 2024-08-15
KR102129220B1 (ko) 2020-07-02
MX350928B (es) 2017-09-26
KR20190035948A (ko) 2019-04-03
CN104039346A (zh) 2014-09-10
KR20160099732A (ko) 2016-08-22
EP2758071B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
BR112014028476A2 (pt) fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
WO2013068563A3 (en) Antibody molecules having specificity for human ox40
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
IL240689B (en) Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX362456B (es) Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
ZA201504952B (en) Human antibodies to respiratory syncytial virus f protein and methods
PT2594588E (pt) Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou andaime proteico não ig anti-adm para utilização em terapia
PL2917229T3 (pl) Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
EP2701705A4 (en) SYNTHETIC TOLEROGENIC NANOTRÄGER FOR REDUCING IMMUNE RESPONSES TO THERAPEUTIC PROTEINS
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
IL231894A0 (en) Compounds and methods for enhancing innate immune responses
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ630881A (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis
SG11201505460WA (en) Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations
BR112013018742A2 (pt) cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática
EP3024482A4 (en) Methods for diagnosing and treating immune disease
LT3173427T (lt) Antikūnai prieš su inkstais susijusį antigeną 1 ir antigeną surišantys jų fragmentai
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
EP3054300A4 (en) Method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk
EP3356548B8 (en) Immunological signatures and parameters predicting therapeutic responses to anti-tnf therapy
EP2879705A4 (en) PEPTIDE VACCINES BASED ON THE EGFRVIII SEQUENCE FOR THE TREATMENT OF TUMORS
HK1234673A1 (en) Methods and compositions for treating allergy and inflammatory diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]